CNTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Centessa Pharmaceuticals PLC (CNTA) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock demonstrates strong technical indicators, positive analyst sentiment, and hedge fund buying activity, which outweigh the insider selling and lack of recent news catalysts. The company's financial performance, while still in losses, shows improving trends, and its lead asset ORX750 has strong potential as per analysts.
The stock's MACD is positive and expanding, RSI is neutral at 66.36, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above key pivot levels, with resistance at 29.854 and 31.098, indicating a bullish trend.
Hedge funds are significantly increasing their positions (+325.14% last quarter), analysts have raised price targets (up to $40), and the company's lead asset ORX750 is gaining traction with high-conviction ratings.
Insiders have increased selling activity (+707.11% last month), and there is no recent news or congress trading data to act as additional positive catalysts.
In Q3 2025, revenue remained at $0, but net income improved by 28.96% YoY to -$54.89M. EPS improved by 10.81% YoY to -0.41, and gross margin remained at 100%. While the company is not yet profitable, the financial trends are improving.
Analysts are bullish, with Wolfe Research initiating coverage with an Outperform rating and a $40 price target. Truist and Needham have also raised price targets, citing strong potential for ORX750 and acquisition attractiveness in 2026.
